Radiopharm Theranostics announces Phase 1 clinical trial milestone

Radiopharm Theranostics (ASX: $RAD) has achieved a significant milestone by dosing the first patient with RAD 204, a PD-L1 nanobody, in a Phase 1 therapeutic trial at Wollongong Hospital, New South Wales. The trial aims to assess the safety and tolerability of 77Lu-RAD204 in PD-L1-positive individuals with metastatic Non-Small Cell Lung Cancer (NSCLC). This achievement underscores Radiopharm's commitment to developing innovative oncology radiotherapeutics.

Executive Commentary on RAD 204 Phase 1 Trial Milestone

Radiopharm's CEO and Managing Director, Riccardo Canevari, expressed delight in achieving this important milestone, emphasizing the unmet medical need in the second-line setting for metastatic NSCLC. He highlighted the potential of RAD 204 to provide an alternative strategy that can improve clinical outcomes for NSCLC patients while preserving their quality of life.

Summary of RAD 204 Phase 1 Trial Milestone

Radiopharm Theranostics (ASX: $RAD) has successfully dosed the first patient with RAD 204 in a Phase 1 therapeutic trial, marking a significant step in the development of transformative oncology radiotherapeutics. The company aims to address the unmet medical need in the second-line setting for metastatic NSCLC and improve clinical outcomes for patients. With the Phase 1 trial underway, Radiopharm is focused on evaluating the safety and preliminary efficacy of RAD 204, demonstrating its commitment to advancing innovative radiopharmaceutical products for areas of high unmet medical need.